Novo Nordisk and OpenAI announced a strategic partnership on April 14 to integrate AI across the Danish pharma's entire business — identifying drug candidates from complex datasets, optimizing manufacturing and supply chain, and upskilling the global workforce in AI literacy. Pilot programs in R&D, manufacturing, and commercial operations are underway, with full integration targeted by end of 2026, structured with data governance guardrails and human oversight requirements. For Novo Nordisk, locked in a GLP-1 weight-loss race with Eli Lilly after losing first-mover advantage, the deal is a direct bet that AI-accelerated pipelines can close the gap.